Multiple sclerosis and related disorders · 2026
Effectiveness and safety of ocrelizumab in relapsing-onset multiple sclerosis: A nationwide real-world study from Slovakia.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vitková Marianna, Szilasiová Jarmila, Fedičová Miriam, Kahancová Edita, Filippi Pavol, Koleňáková Katarína, Kiačiková Mária, Dziaková Jana, Bilá Anna, Laurincová Silvia, Koleda Peter, Kováčová Slavomíra, Hančinová Viera, Bullová Andrea, Kantorová Ema, Karlík Martin, Slezáková Darina
Аннотация
BACKGROUND: Ocrelizumab (OCR) is a high-efficacy anti-CD20 monoclonal antibody approved for multiple sclerosis (MS) treatment. This nationwide real-world study evaluated the effectiveness and safety of OCR in patients with relapsing-onset MS (ROMS) in Slovakia.
METHODS: This multicenter retrospective study included 499 patients with ROMS treated between January 2019 and January 2024. Outcomes included annualized relapse rate (ARR), confirmed disability progression (6mCDP), MRI activity, NEDA-3, and safety parameters.
RESULTS: During a mean follow-up of 2.4 years, ARR decreased from 1.1 to 0.04; 6mCDP occurred in 7.1% of patients, and NEDA-3 was achieved in 75.5%. OCR was well tolerated with infusion-related reactions (12.2%) and infections (<6%) as the most common adverse events.
CONCLUSIONS: OCR demonstrated high effectiveness and a favorable safety profile in routine clinical practice, supporting early initiation of high-efficacy therapy in relapsing-onset MS.
METHODS: This multicenter retrospective study included 499 patients with ROMS treated between January 2019 and January 2024. Outcomes included annualized relapse rate (ARR), confirmed disability progression (6mCDP), MRI activity, NEDA-3, and safety parameters.
RESULTS: During a mean follow-up of 2.4 years, ARR decreased from 1.1 to 0.04; 6mCDP occurred in 7.1% of patients, and NEDA-3 was achieved in 75.5%. OCR was well tolerated with infusion-related reactions (12.2%) and infections (<6%) as the most common adverse events.
CONCLUSIONS: OCR demonstrated high effectiveness and a favorable safety profile in routine clinical practice, supporting early initiation of high-efficacy therapy in relapsing-onset MS.